S-23 vs LGD-4033: Comparing Development and Research
S-23 and LGD-4033 (Ligandrol) are selective androgen receptor modulators, or SARMs. They are often compared in performance-related research discussions, but their development literature is not interchangeable. The useful comparison is the type of evidence available, the model studied and the question each study asked—not which compound promises a better outcome.
The key distinction: different research settings
A published S-23 study examined receptor activity and hormonal-contraception research in rats. A published early LGD-4033 clinical study examined safety, tolerability and pharmacokinetics in healthy adult men. These are different experimental settings and objectives; neither paper is a head-to-head comparison of the two compounds.
S-23: preclinical development context
The Jones and colleagues paper published in Endocrinology in 2009 investigated S-23 as a nonsteroidal androgen-receptor ligand in preclinical models. It included a rat hormonal-contraception model. This describes the research programme, not a permitted use for a commercial product or evidence that the findings transfer directly to humans.
Read the S-23 research overview for further terminology and background.
LGD-4033: early clinical research context
The Basaria and colleagues paper published in 2013 reports an early clinical investigation of LGD-4033 in healthy men. Pharmacokinetic measurements describe a compound's behaviour in the particular study conditions. They do not establish broad safety, suitability for self-directed use, or equivalence between a research study material and a retail product.
Read the Ligandrol (LGD-4033) research overview for a focused introduction.
How to compare the evidence
- Study model: distinguish cell, animal and human evidence. Do not collapse them into a single ranking.
- Research question: a receptor-binding measurement, a pharmacokinetic investigation and a clinical endpoint answer different questions.
- Study limitations: population, duration and design constrain what can be concluded. An early study does not settle every safety question.
- Material identity: the compound name is not a substitute for product identity, lot records or appropriate analytical evidence.
Frequently asked questions
Are S-23 and LGD-4033 the same compound?
No. They share a broad research classification but have different chemical identities and development histories. “SARM” does not mean that compounds are equivalent.
Does receptor selectivity mean no adverse effects?
No. Selectivity describes a particular interaction or experimental observation. It is not a general guarantee of safety.
Can these studies identify the better product for personal use?
No. This guide does not rank compounds for personal use. It explains why different research settings cannot be treated as a direct product comparison.
Documentation and related resources
Consult the Lab Analysis library and purity and testing guide to understand report dates, identity testing and batch limitations. Product-format information is available on the S-23 listing and Ligandrol listing.
Sources
- Jones et al. (2009): S-23 preclinical development and rat hormonal-contraception study.
- Basaria et al. (2013): early clinical safety, tolerability and pharmacokinetic investigation of LGD-4033.
Research-only and legal context
Supplied for research purposes only. NutriMax products are not for human or veterinary use or consumption. This page provides no dosage, cycle, stacking or administration guidance and makes no medical, therapeutic or performance-outcome claim. Consult our Global Legality Guide and verify requirements in the relevant jurisdiction; a research-only description does not itself establish legal permission.